Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT01236391Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Feb 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Pharmacyclics. Started Feb 2011; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01236391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01236391.